Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:16 AM
Ignite Modification Date:
2025-12-25 @ 3:16 AM
NCT ID:
NCT00296205
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of secondary progressive (SPMS), primary progressive (PPMS) or progressive relapsing (PRMS) multiple sclerosis
* A diagnosis of MS will be established by fulfilling criteria "Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the Internal Panel on the Diagnosis of Multiple Sclerosis"
* The subtype of MS will be established by the natural history of the disease
* Age \>18 but \< 75 years
* An extended disability status scale (EDSS) score of \>3.5 after two standard treatment regimens IFNB1a IFNB1b Glatiramer acetate Mitoxanthrone Steroids, plasmapheresis or IVIG individually or in combination constitute a single treatment regimen
* Patient must have a left ventricular ejection fraction of \> 45%
* Serum Creatinine \<3mg/dL
* For women of childbearing potential, serum βHCG (less than seven days before start of cyclophosphamide)
* Willingness to participate in a clinical trial
Exclusion Criteria:
* Patients who are preterminal or moribund
* Patients with active malignancies
* Patients with chromosomal abnormalities or peripheral blood counts suggestive of myelodysplastic syndrome
* Patients with active bacterial or fungal infections requiring oral or intravenous antimicrobials are not eligible until resolution of the infection
* Pregnant women and breast-feeding women
* Patients with known intolerance to G-CSF
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT00296205
Study Brief:
Protocol Section:
NCT00296205